BridgeBio Pharma, Inc. (BBIO - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 11.8% in the past one-month time frame.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
BridgeBio Pharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
BridgeBio Pharma, Inc. Price
Investors interested in the Medical – Generic Drugs industry may consider Dr. Reddy's Laboratories Limited (RDY - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BBIO going up? Or down? Predict to see what others think:Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>